

SHORT
COMMUNICATIONS

Oxidation of 3-Acetoxy-17 β -nitroxyestra-1,3,5(10)-triene with Ceric Ammonium Nitrate in the Synthesis of Steroid Dinitrates*

L. E. Golubovskaya and V. M. Rzheznikov

*Institute of Experimental Endocrinology, Endocrinological Scientific Center,
Russian Academy of Medical Sciences, Moscow, 117036 Russia*


Received November 1, 2000

Among the few steroid nitrates attention of researchers is attracted by O-nitroestrogens, and first of all 11- β -nitroxyestra-1,3,5(10)-trienes that possess both the predictable estrogen activity [1] and unexpected cardioprotective qualities [2]. In the light of the latest data and by analogy with the known cardioactive organic dinitrates [3] it was presumable that O-dinitroestrogens **II**, **III** would show anti-ischemia activity, and therefore the present study was devoted to their preparation. In the synthesis of steroid nitrates the nitration is usually performed with acetyl nitrate [4], and only with estrogens is reported a direct introduction of ONO₂ group into a steroid with ceric ammonium nitrate [5].

We applied both the procedures in succession including previously not described oxidation of compound **Ib** with ceric ammonium nitrate. The special interest in this process regards the reaction stereochemistry where alongside the products with the natural 9 α -configuration of the hydroxy group as in compound **II** may arise the 9 β -epimers [5, 6]. The existing data on effect of the substituent in C¹⁷ position on the stereodirection of oxidation are ambiguous [5, 7]. Therefore apart the synthesis of steroid dinitrates among which only compound **III** was shortly described in a patent [8] the target of this work consisted in evaluation of isomer composition of the oxidation products arising from **Ib**. The latter compound was obtained from estradiol **Ia** acetate by the known procedure [9].

The treatment of mononitrate **Ib** with 5.5 equiv of ceric ammonium nitrate in acetic acid resulted mainly

in dinitrate (**II**). Its 9 β -epimer was revealed in the mixture with dinitrate **II** by means of ¹H NMR spectroscopy by appearance of additional signals of the angular CH₃ group and of the proton at C¹⁷ atom that were shifted downfield with respect to the principal signals of the mentioned protons in agreement with the published data [5, 10]. The 9 α - to 9 β -epimer ratio was 7:3 according to HPLC analysis, close to our data for the best known estrogens [7]. This fact apparently evidences that the direction of oxidation of steroids with aromatic A ring is independent of the substituent in C¹⁷ position.



R = H (**a**), NO₂ (**b**).

* The study was carried out under financial support of the Russian Foundation for Basic Research (grant no. 00-03-32848).

To eliminate the 9 α -hydroxy group in steroid **II** and to convert it into compound **III** we carried out ionic hydrogenation with triethylsilane in the presence of boron trifluoride etherate that resulted as already had been described [6] in hydrogenolysis of benzyl hydroxy group. We obtained dinitrate **III** in 41% yield.

3-Acetoxy-9 α -hydroxy-11 β ,17 β -dinitroxyestra-1,3,5(10)-triene (II). To a solution of 1 g (2.79 mmol) of nitrate **Ib**, mp 106–108°C (publ. 107–109°C [9]), in 50 ml of glacial acetic acid was added a solution of 8.4 g (15.35 mmol) of ceric ammonium nitrate in 6.5 ml of water. The orange solution was stirred for 2 h at 20°C, then diluted by equal amount of water, the reaction products were extracted into chloroform. The extract was washed with 10% solution of NaHCO₃ and dried on MgSO₄. The solvent was evaporated, the residue was dissolved in benzene, filtered rapidly through 10 g of neutral Al₂O₃ (**II** activity grade), and additionally eluted with 50 ml of benzene. We separated 1.03 g of oily substance containing mainly a mixture of dinitrate **II** with its 9 β -epimer in 7:3 ratio (data of HPLC, retention times 8.4 and 7.6 min respectively).

¹H NMR spectrum (δ , ppm): 1.01 s and 1.10 s (CH₃), 2.29 s (OAc), 4.68 t and 4.97 t (C¹⁷H), 5.77 br.s and 6.12 br.s (C¹¹H), 6.9–7.6 m (H arom). By grinding the mixture under ether we separated 317 mg of colorless crystals of dinitrate **II**, mp 181–183°C (from ethyl acetate–hexane mixture), $[\alpha]_D^{20} +43 \pm 2^\circ$. IR spectrum, cm⁻¹: 3450 (OH), 1740, 1280 (OAc), 1630 (ONO₂), 1490 (C=C arom). ¹H NMR spectrum (δ , ppm): 1.01 s (3H, CH₃), 2.29 s (3H, OAc), 4.97 t (1H, C¹⁷H, *J* 7.7 Hz), 5.77 br.s (1H, C¹¹H), 6.92 m (2H, C²H + C⁴H), 7.28 d (1H, C¹H, *J* 8.5 Hz). Found, %: N 6.34. C₂₀H₂₄N₂O₉. Calculated, %: N 6.42.

3-Acetoxy-11 β ,17 β -dinitroxyestra-1,3,5(10)-triene (III). To a solution of 100 mg (0.23 mmol) of dinitrate **II** in 2 ml of anhydrous CH₂Cl₂ under argon atmosphere at 20°C was added 0.2 ml (1.26 mmol) of Et₃SiH and at -10°C was added 0.3 ml (2.43 mmol) of freshly distilled boron trifluoride etherate. The yellow solution was stirred for 30 min, was added 10% NaHCO₃ till the solution became colorless, and the reaction mixture was diluted with chloroform–water mixture. The extract was dried on MgSO₄, the residue after evaporation of the solvent was crystallized by grinding under ether. We isolated 40 mg (41%) of dinitrate **III**, mp 157–159°C (from

ethyl acetate–hexane mixture), $[\alpha]_D^{20} +40 \pm 4^\circ$ (publ.: mp 160–161°C, $[\alpha]_D^{20} +35.6^\circ$ [8]). IR spectrum, cm⁻¹: 1760, 1620, 1490. ¹H NMR spectrum (δ , ppm): 1.05 s and 2.30 s (each 3H), 4.74 t (1H, *J* 7.5 Hz), 5.94 m (1H), 6.91 m (2H), 7.41 d (1H, *J* 8.5 Hz).

Melting points were measured on the Boëtius heating block. The optical rotation was measured on Polamat A polarimeter from chloroform solutions (*c* 1.0–1.05). IR spectra were recorded of Specord 75 IR spectrophotometer from KBr pellets. ¹H NMR spectra were registered on spectrometer Tesla BS-587 A (80 MHz) in CDCl₃, internal reference TMS. The HPLC analysis was carried out on Millichrom11 instrument equipped with UV detector at wavelength 230 nm, column 80×2mm packed with Silasorb C₁₈, eluent acetonitrile–water, 3:2.

REFERENCES

1. Rzheznikov, V.M., Ivanenko, T.I., Pokrovskaya, E.V., and Fedotov, V.P., *Khim.-Farm. Zh.*, 1986, vol. 20, no. 9, pp. 1057–1061; Peters, R.H., Crowe, D.F., Avery, M.A., and Chong, W.K.M., *J. Med. Chem.*, 1989, vol. 32, pp. 2306–2310.
2. Sergeev, P.V., Karachentsev, A.N., Dukhanin, A.S., Golubovskaya, L.E., and Rzheznikov, V.M., Abstracts of Papers, *2nd Int. Symp. Chem., Natur. Comp.*, Eskisehir, Turkey, 1996.
3. Mashkovskii M.D., *Lekarstvennye sredstva* (Drugs), Moscow: Meditsina, 1993, vol. 1, pp. 485–496.
4. *Zashchitnye gruppy v organicheskoi khimii* (Protective groups in Organic Chemistry), Makomi, J., Moscow: Mir, 1976.
5. Sykes, P.J., Rutherford, F.G., Laing, S.B., Phillips, J.H., and Turnbull, J.P., *Tetrahedron Lett.*, 1971, no. 37, pp. 3393–3396.
6. Golubovskaya, L.E. and Rzheznikov, V.M., *Zh. Org. Khim.*, 1997, vol. 33, no. 4, pp. 617–618; 1998, vol. 34, no. 12, pp. 1874–1875.
7. Rzheznikov, V.M., Golubovskaya, L.E., Minailova, O.N., and Tolkachev, V.N., Abstracts of Papers, *XVIIth Mendeleev Meeting on General and Applied Chemistry*, St. Petersburg, 1998.
8. US Patent 9507925, 1995; *Chem. Abstr.*, 1995, vol. 123, 56390.
9. Rzheznikov, V.M., Golubovskaya, L.E., Shevelev, S.A., and Shakhnes, A.Kh., *Izv. Akad. Nauk, Ser. Khim.*, 1999, no. 6, pp. 1195–1197.
10. Rzheznikov, V.M., *Bioorg. khimiya*, 1991, vol. 17, no. 7, pp. 1057–1061.